Vol 73, No 1 (2022)
Review paper
Published online: 2021-10-06

open access

Page views 6834
Article views/downloads 904
Get Citation

Connect on Social Media

Connect on Social Media

The outstanding beneficial roles of irisin disorders

Saadet Ilcın1, Sermın Algül1, Oguz Ozcelık2
Pubmed: 34647610
Endokrynol Pol 2022;73(1):149-156.


Depression is a widely observed psychiatric disorder that affects a quite large number of people all around the world. A major depressive disorder (MDD) is a multifactorial disease that IS associated with fluctuations in appetite, body weight, and energy situations in addition to serious mood problems. The aim of this review is to investigate a possible link between energy regulatory hormones of irisin and depressive disorders.

Irisin is a hormone that plays a significant role in the regulation of lipid and glucose metabolism in skeletal muscle and adipose tissue. Irisin was also reported to play significant roles in the central nervous system. In the literature there are reports indicating a beneficial antidepressant role of irisin in MDD.

It should be emphasised that the antidepressive effects of exercise could be the result of exercise-induced increased hormones of irisin.

Article available in PDF format

View PDF Download PDF file


  1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008; 358(1): 55–68.
  2. DSM-IV-TR A. American Psychiatric Association . DSM-IV-TR A. Diagnostic and statistical manual of mental disorders. APA, Washington, DC 2000.
  3. Malhi G, Mann J. Depression. Lancet. 2018; 392(10161): 2299–2312.
  4. Ozamiz-Etxebarria N, Dosil-Santamaria M, Picaza-Gorrochategui M, et al. Stress, anxiety, and depression levels in the initial stage of the COVID-19 outbreak in a population sample in the northern Spain. Cad Saude Publica. 2020; 36: 00054020.
  5. Özdin S, Bayrak Özdin Ş. Levels and predictors of anxiety, depression and health anxiety during COVID-19 pandemic in Turkish society: The importance of gender. Int J Soc Psychiatry. 2020; 66(5): 504–511.
  6. Torales J, O'Higgins M, Castaldelli-Maia JM, et al. The outbreak of COVID-19 coronavirus and its impact on global mental health. Int J Soc Psychiatry. 2020; 66(4): 317–320.
  7. Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020; 89: 531–542.
  8. Algul S, Ozcelik O. Evaluating the Levels of Nesfatin-1 and Ghrelin Hormones in Patients with Moderate and Severe Major Depressive Disorders. Psychiatry Investig. 2018; 15(2): 214–218.
  9. Kim S, Choi JY, Moon S, et al. Roles of myokines in exercise-induced improvement of neuropsychiatric function. Pflugers Arch. 2019; 471(3): 491–505.
  10. Boström P, Wu J, Jedrychowski MP, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481(7382): 463–468.
  11. Ferrer-Martínez A, Ruiz-Lozano P, Chien KR. Mouse PeP: a novel peroxisomal protein linked to myoblast differentiation and development. Dev Dyn. 2002; 224(2): 154–167.
  12. Teufel A, Malik N, Mukhopadhyay M, et al. Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene. 2002; 297(1-2): 79–83.
  13. Erickson HP. Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte. 2013; 2(4): 289–293.
  14. Schumacher MA, Chinnam N, Ohashi T, et al. The structure of irisin reveals a novel intersubunit β-sheet fibronectin type III (FNIII) dimer: implications for receptor activation. J Biol Chem. 2013; 288(47): 33738–33744.
  15. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738.
  16. Piya MK, Harte AL, Sivakumar K, et al. The identification of irisin in human cerebrospinal fluid: influence of adiposity, metabolic markers, and gestational diabetes. Am J Physiol Endocrinol Metab. 2014; 306(5): E512–E518.
  17. Dun SL, Lyu RM, Chen YH, et al. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience. 2013; 240: 155–162.
  18. Wrann CD, White JP, Salogiannnis J, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013; 18(5): 649–659.
  19. Xu B. BDNF (I)rising from exercise. Cell Metab. 2013; 18(5): 612–614.
  20. Park H, Popescu A, Poo Mm. Essential role of presynaptic NMDA receptors in activity-dependent BDNF secretion and corticostriatal LTP. Neuron. 2014; 84(5): 1009–1022.
  21. Ahlskog JE. Does vigorous exercise have a neuroprotective effect in Parkinson disease? Neurology. 2011; 77(3): 288–294.
  22. Arida RM, Cavalheiro EA, da Silva AC, et al. Physical activity and epilepsy: proven and predicted benefits. Sports Med. 2008; 38(7): 607–615.
  23. Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007; 30(9): 464–472.
  24. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology. 1999; 21(5): 679–682.
  25. Zhang H, Lee JY, Borlongan CV, et al. A brief physical activity protects against ischemic stroke. Brain Circ. 2019; 5(3): 112–118.
  26. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4): E769–E778.
  27. Roca-Rivada A, Castelao C, Senin LL, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013; 8(4): e60563.
  28. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6): 324–337.
  29. Algul S, Ozdenk C, Ozcelik O. Variations in leptin, nesfatin-1 and irisin levels induced by aerobic exercise in young trained and untrained male subjects. Biol Sport. 2017; 34(4): 339–344.
  30. Ozcelik O, Algul S, Yilmaz B. Nesfatin-1 and irisin levels in response to the soccer matches performed in morning, afternoon and at night in young trained male subjects. Cell Mol Biol (Noisy-le-grand). 2018; 64(10): 130–133.
  31. Brown HE, Pearson N, Braithwaite RE, et al. Physical activity interventions and depression in children and adolescents : a systematic review and meta-analysis. Sports Med. 2013; 43(3): 195–206.
  32. Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms: Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018; 75(6): 566–576.
  33. Lee P, Linderman JD, Smith S, et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014; 19(2): 302–309.
  34. Phillips C, Baktir MA, Srivatsan M, et al. Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling. Front Cell Neurosci. 2014; 8: 170.
  35. Xiong XQ, Chen D, Sun HJ, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. Biochim Biophys Acta. 2015; 1852(9): 1867–1875.
  36. Rosell M, Kaforou M, Frontini A, et al. Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice. Am J Physiol Endocrinol Metab. 2014; 306(8): E945–E964.
  37. Cannon B, Nedergaard J, Zhao J, et al. Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cells. Am J Physiol. 1994; 267(4 Pt 1): C969–C979.
  38. DAVIS TR, DAVIS TR. Chamber cold acclimatization in man. Rep US Army Med Res Lab. 1961; 475: 1–8.
  39. Li F, Li Y, Duan Y, et al. Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue. Cytokine Growth Factor Rev. 2017; 33: 73–82.
  40. Steiner JL, Murphy EA, McClellan JL, et al. Exercise training increases mitochondrial biogenesis in the brain. J Appl Physiol (1985). 2011; 111(4): 1066–1071.
  41. Zsuga J, Biro K, Papp C, et al. The "proactive" model of learning: Integrative framework for model-free and model-based reinforcement learning utilizing the associative learning-based proactive brain concept. Behav Neurosci. 2016; 130(1): 6–18.
  42. Schott BH, Minuzzi L, Krebs RM, et al. Mesolimbic functional magnetic resonance imaging activations during reward anticipation correlate with reward-related ventral striatal dopamine release. J Neurosci. 2008; 28(52): 14311–14319.
  43. Leyton M. The neurobiology of desire: Dopamine and the regulation of mood and motivational states in humans. In: Kringelbach ML, Berridge KC. ed. Pleasures of the brain. Oxford University Press, Oxford 2010: 222–243.
  44. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend. 1995; 38(2): 95–137.
  45. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006; 30(2): 215–238.
  46. Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991; 350(6315): 230–232.
  47. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006; 59(12): 1151–1159.
  48. Walsh JJ, Friedman AK, Sun H, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nat Neurosci. 2014; 17(1): 27–29.
  49. Cabib S, Puglisi-Allegra S, Imperato A, et al. Genotype-dependent adaptation of mesolimbic dopamine system and stress-induced behavioral sensitization to amphetamine. Clin Neuropharmacol. 1992; 15 Suppl 1 Pt A(1-2): 251A–252A.
  50. Mucher P, Batmyagmar D, Perkmann T, et al. Basal myokine levels are associated with quality of life and depressed mood in older adults. Psychophysiology. 2021; 58(5): e13799.
  51. Hofmann T, Elbelt U, Ahnis A, et al. The exercise induced myokine irisin does not show an association with depressiveness, anxiety and perceived stress in obese women. J Physiol Pharmacol. 2016; 67: 195–203.
  52. Opmeer EM, Kortekaas R, Aleman A. Depression and the role of genes involved in dopamine metabolism and signalling. Prog Neurobiol. 2010; 92(2): 112–133.
  53. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014; 140(3): 774–815.
  54. Huys QJm, Pizzagalli DA, Bogdan R, et al. Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. Biol Mood Anxiety Disord. 2013; 3(1): 12.
  55. Wu C, Lu J, Lu S, et al. Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia. J Psychiatr Res. 2020; 126: 92–97.
  56. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006; 311(5762): 864–868.
  57. Tu WJ, Qiu HC, Liu Q, et al. Decreased level of irisin, a skeletal muscle cell-derived myokine, is associated with post-stroke depression in the ischemic stroke population. J Neuroinflammation. 2018; 15(1): 133.
  58. Szilasi ME, Pak K, Kardos L, et al. The Alteration of Irisin-Brain-Derived Neurotrophic Factor Axis Parallels Severity of Distress Disorder in Bronchial Asthma Patients. Front Neurosci. 2017; 11: 653.
  59. Wang S, Pan J. Irisin ameliorates depressive-like behaviors in rats by regulating energy metabolism. Biochem Biophys Res Commun. 2016; 474(1): 22–28.
  60. Altar CA, Laeng P, Jurata LW, et al. Neurotrophins and depression. Trends Pharmacol Sci. 1999; 20(2): 59–61.
  61. Hou Z, Zhang J, Yu Ke, et al. Irisin ameliorates the postoperative depressive-like behavior by reducing the surface expression of epidermal growth factor receptor in mice. Neurochem Int. 2020; 135: 104705.
  62. Normanno N, De Luca A, Bianco C, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005; 6(3): 243–257.
  63. Austin S, St-Pierre J. PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012; 125(Pt 21): 4963–4971.
  64. Siteneski A, Cunha MP, Lieberknecht V, et al. Central irisin administration affords antidepressant-like effect and modulates neuroplasticity-related genes in the hippocampus and prefrontal cortex of mice. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84(Pt A): 294–303.
  65. Ignácio ZM, da Silva RS, Plissari ME, et al. Physical Exercise and Neuroinflammation in Major Depressive Disorder. Mol Neurobiol. 2019; 56(12): 8323–8335.
  66. Blumenthal JA, Babyak MA, Doraiswamy PM, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med. 2007; 69(7): 587–596.
  67. Olson RL, Brush CJ, Ehmann PJ, et al. A randomized trial of aerobic exercise on cognitive control in major depression. Clin Neurophysiol. 2017; 128(6): 903–913.
  68. Gourgouvelis J, Yielder P, Murphy B. Exercise Promotes Neuroplasticity in Both Healthy and Depressed Brains: An fMRI Pilot Study. Neural Plast. 2017; 2017: 8305287.
  69. Phillips C, Fahimi A. Immune and Neuroprotective Effects of Physical Activity on the Brain in Depression. Front Neurosci. 2018; 12: 498.
  70. Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019; 102: 56–84.
  71. Siteneski A, Olescowicz G, Pazini FL, et al. Antidepressant-like and pro-neurogenic effects of physical exercise: the putative role of FNDC5/irisin pathway. J Neural Transm (Vienna). 2020; 127(3): 355–370.
  72. Kheirbek MA, Hen R. Dorsal vs ventral hippocampal neurogenesis: implications for cognition and mood. Neuropsychopharmacology. 2011; 36(1): 373–374.
  73. Carpenter KM, Hasin DS, Allison DB, et al. Relationships between obesity and DSM-IV major depressive disorder, suicide ideation, and suicide attempts: results from a general population study. Am J Public Health. 2000; 90(2): 251–257.
  74. Faith MS, Matz PE, Jorge MA. Obesity-depression associations in the population. J Psychosom Res. 2002; 53(4): 935–942.
  75. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007; 62(4): 321–326.
  76. Onyike CU, Crum RM, Lee HB, et al. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003; 158(12): 1139–1147.
  77. Blaine B. Does depression cause obesity?: A meta-analysis of longitudinal studies of depression and weight control. J Health Psychol. 2008; 13(8): 1190–1197.
  78. de Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010; 178(2): 230–235.
  79. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67(3): 220–229.
  80. Hou N, Han F, Sun X. The relationship between circulating irisin levels and endothelial function in lean and obese subjects. Clin Endocrinol (Oxf). 2015; 83(3): 339–343.
  81. Timmons JA, Baar K, Davidsen PK, et al. Is irisin a human exercise gene? Nature. 2012; 488(7413): E9–10; discussion E10.
  82. Knol MJ, Twisk JWR, Beekman ATF, et al. Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia. 2006; 49(5): 837–845.
  83. Mezuk B, Eaton WW, Albrecht S, et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2008; 31(12): 2383–2390.
  84. Nefs G, Pouwer F, Denollet J, et al. The course of depressive symptoms in primary care patients with type 2 diabetes: results from the Diabetes, Depression, Type D Personality Zuidoost-Brabant (DiaDDZoB) Study. Diabetologia. 2012; 55(3): 608–616.
  85. Duran ID, Gülçelik NE, Ünal M, et al. Irisin levels in the progression of diabetes in sedentary women. Clin Biochem. 2015; 48(18): 1268–1272.
  86. Du XL, Jiang WX, Lv ZT. Lower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Horm Metab Res. 2016; 48(10): 644–652.
  87. Liu JJ, Wong MDS, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013; 27(4): 365–369.
  88. Yan B, Shi X, Zhang H, et al. Association of serum irisin with metabolic syndrome in obese Chinese adults. PLoS One. 2014; 9(4): e94235.
  89. Lin H, Yuan Y, Tian S, et al. In Addition to Poor Glycemic Control, a High Level of Irisin in the Plasma Portends Early Cognitive Deficits Clinically in Chinese Patients With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2019; 10: 634.